| Entry |
|
|---|
| Name |
Imatinib mesilate (JAN);
Imatinib mesylate (USAN);
Gleevec (TN);
Glivec (TN)
|
|---|
| Product |
|
|---|
| Formula |
C29H31N7O. CH4SO3
|
|---|
| Exact mass |
589.2471
|
|---|
| Mol weight |
589.7084
|
|---|
| Structure |
     |
|---|
| Activity |
Antileukemia and other antitumor agent (tyrosine kinase inhibitor) [DS: H00001 H00004]
|
|---|
| Remark |
Therapeutic category: ATC code: |
|---|
| Comment |
(1) Aggressive systemic mastocytosis (ASM) - for patients without D816V c-Kit mutation
(2) Chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) - for Philadelphia chromosome positive patients
(3) Myelodysplastic/myeloproliferative diseases (MDS/MPD) - for patients with PDGFR gene rearrangements
(4) Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) - for patients who have FIP1L1-PDGFR alpha fusion kinase and who are FIP1L1-PDGFR alpha fusion kinase negative or unknown
|
|---|
| Target |
Bcr-Abl tyrosine kinase inhibitor [HSA: 25] [KO: K06619]; PDGFRA tyrosine kinase inhibitor [HSA: 5156] [KO: K04363]; PDGFRB tyrosine kinase inhibitor [HSA: 5159] [KO: K05089]; c-KIT tyrosine kinase inhibitor [HSA: 3815] [KO: K05091] |
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576], CYP3A5 [HSA: 1577], CYP2D6 [HSA: 1565], CYP2C9 [HSA: 1559]
Transporter: ABCB1 [HSA: 5243], ABCG2 [HSA: 9429]
|
|---|
| Interaction |
Genomic biomarker: (1) KIT mutation [HSA: 3815], (2) Philadelphia chromosome, (3) PDGFR [HSA: 5156 5159], (4) FIP1L1-PDGFRA fusion gene [HSA: 81608 5156]
CYP inhibition: CYP3A [KO: K07424], CYP2D6 [HSA: 1565]
 |
|---|
| Structure map |
| Antineoplastics - protein kinases inhibitors |
|
|---|
| Brite |
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D01441 Imatinib mesilate (JAN); Imatinib mesylate (USAN)
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XE Protein kinase inhibitors
L01XE01 Imatinib
D01441 Imatinib mesilate (JAN); Imatinib mesylate (USAN)
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Multitargeted Kinase Inhibitors, Bcr-Abl / c-kit Receptor Tyrosine Kinase Inhibitors
Imatinib
D01441 Imatinib mesilate (JAN); Imatinib mesylate (USAN)
Target-based classification of drugs [BR:br08310]
Cytokine receptors
Receptor tyrosine kinase
RTK class III (PDGF receptor family)
PDGFRA tyrosine kinase [HSA:5156] [KO:K04363]
Imatinib [ATC:L01XE01]
D01441 Imatinib mesilate (JAN)
PDGFRB tyrosine kinase [HSA:5159] [KO:K05089]
Imatinib [ATC:L01XE01]
D01441 Imatinib mesilate (JAN)
c-KIT tyrosine kinase [HSA:3815] [KO:K05091]
Imatinib [ATC:L01XE01]
D01441 Imatinib mesilate (JAN)
Protein kinases
Tyrosine protein kinases
Abl family
Bcr-Abl tyrosine kinase [HSA:25] [KO:K06619]
Imatinib [ATC:L01XE01]
D01441 Imatinib mesilate (JAN)
Antineoplastics [BR:br08308]
Molecularly targeted agents
Receptor tyrosine kinase inhibitors
Imatinib [ATC:L01XE01]
D01441 Imatinib mesilate (JAN); Imatinib mesylate (USAN)
 |
|---|
| Other DBs |
CAS: 220127-57-1 PubChem: DrugBank: LigandBox: NIKKAJI: |
|---|
| KCF data |
ATOM 42
1 C8x C 33.4600 -13.6500
2 C8y C 33.4600 -12.2500
3 C8x C 32.2700 -11.5500
4 C8x C 31.0100 -12.2500
5 C8y C 31.0100 -13.6500
6 C8x C 32.2700 -14.3500
7 C5a C 29.8200 -14.3500
8 N1b N 28.6300 -13.6500
9 C8y C 27.4400 -14.3500
10 C8x C 26.1800 -13.6500
11 C8y C 24.9900 -14.3500
12 C8y C 24.9900 -15.7500
13 C8x C 26.1800 -16.4500
14 C8x C 27.4400 -15.7500
15 N1b N 23.8000 -13.7200
16 C8y C 22.5400 -14.4200
17 N5x N 21.3500 -13.7200
18 C8y C 20.1600 -14.4200
19 C8x C 20.1600 -15.8200
20 C8x C 21.3500 -16.5200
21 N5x N 22.5400 -15.8200
22 C8y C 18.9000 -13.7200
23 C8x C 18.9000 -12.3200
24 N5x N 17.7100 -11.6200
25 C8x C 16.5200 -12.3200
26 C8x C 16.5200 -13.7200
27 C8x C 17.7100 -14.4200
28 C1b C 34.6500 -11.5500
29 N1y N 35.9100 -12.2500
30 C1x C 35.9100 -13.6500
31 C1x C 37.1000 -14.3500
32 N1y N 38.2900 -13.6500
33 C1x C 38.2900 -12.2500
34 C1x C 37.1000 -11.5500
35 C1a C 39.5500 -14.3500
36 O5a O 29.8200 -15.7500
37 C1a C 23.8000 -16.4500
38 S4a S 34.9300 -16.5900
39 O1d O 34.9300 -15.1900
40 O1d O 34.9300 -17.9900
41 C1a C 33.5300 -16.5900
42 O1d O 36.3300 -16.5900
BOND 45
1 18 19 2
2 19 20 1
3 20 21 2
4 21 16 1
5 3 4 2
6 18 22 1
7 4 5 1
8 5 6 2
9 6 1 1
10 9 10 2
11 10 11 1
12 22 23 2
13 23 24 1
14 24 25 2
15 25 26 1
16 26 27 2
17 27 22 1
18 11 12 2
19 2 28 1
20 12 13 1
21 28 29 1
22 13 14 2
23 14 9 1
24 11 15 1
25 5 7 1
26 29 30 1
27 30 31 1
28 31 32 1
29 32 33 1
30 33 34 1
31 34 29 1
32 15 16 1
33 32 35 1
34 7 36 2
35 7 8 1
36 12 37 1
37 1 2 2
38 8 9 1
39 2 3 1
40 16 17 2
41 17 18 1
42 38 39 2
43 38 40 2
44 38 41 1
45 38 42 1
|
|---|
